Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2012

Cancer Sequencing Gets the Geospiza Treatment

  • PerkinElmer is teaming up with researchers at the Massachusetts General Hospital (MGH) Pathology Department and Cancer Center to develop and implement a cancer gene sequencing informatics system based on the firm’s Geospiza® platform. The new system will support cancer research by the MGH facility’s John Iafrate, M.D., and Long Le, M.D., and is ultimately hoped to aid cancer treatment guidance based on genotype analysis.

    “A key challenge presented by next-generation sequencing applications in clincial research is not only maintaining high-efficiency throughput via automation solutions, but also ensuring that the informatics driving the instrumentation provides transparency and traceability for the entire process,” Dr. Le comments.

    Under terms of the deal PerkinElmer will develop an automated sample preparation and data analysis system for use in clinical research cancer genotyping at the MGH. The new system will include enhancements to the Geospiza GeneSifter® Laboratory and Analysis edition software platform with variant detection algorithms, and integrate existing laboratory processes and equipment with LIMS and data analysis capabilities.

    PerkinElmer acquired Geospiza in May 2011 to take over the firm’s software systems for the management of genetic analysis data. The firm’s flagship GeneSifter Lab Edition platform is an out-of-the-box lab management system for next-generation sequencing data management and analysis. Its enterprise GeneSiftware Analysis Edition is a cloud-based portal for the analysis of microarray and next-generation sequencing data.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »